Assessment of left ventricular diastolic dysfunction following anthracyclinebased chemotherapy in breast cancer patients

Cardiotoxicity is a side effect of anthracycline-based chemotherapy. Clinical and prognostic significance of left ventricular diastolic dysfunction in heart failure patients is undeniable.
The aim. To assess dynamic changes in the left ventricular diastolic function after anthracycline-based chemotherapy (ANT) in breast cancer patients.
Material and methods. The study included 40 women aged 35 to 72 years with breast cancer (BC) undergoing ANT chemotherapy. The main group (n = 40) consisted of women with breast cancer examined at admission, after 6 months the same women (n = 37) were examined again. Women without breast cancer (n = 25) were used as the control group.
Results. Dynamic changes in mitral annular velocities were revealed by Doppler tissue imaging. Lateral early diastolic mitral annular velocity (e’ lateral) was significantly lower in breast cancer patients as compared to the control group (p = 0.031). Six months after ANT chemotherapy, there was a definite increase in the lateral late diastolic mitral annular velocity (a’ lateral) (p = 0.033). Average early diastolic transmitral flow velocity to early diastolic velocity (E/e’ lateral) ratio was within the normative values in all groups, but E/e’ lateral in the main group was higher compared to the control group (p = 0.003). In the main group, septal early diastolic mitral annular velocity (e’ septal) was lower compared to the control group (p = 0.0005). Moreover, an increase in the septal mitral annular velocity (a’ septal) (p = 0.01) and higher E/e’ septal ratio (p = 0.011) were revealed during dynamic observation. Multiple logistic regression disclosed that E/A, e’ lateral, e’/a’ lateral, and E/e’ lateral were affected by heart rate, psychological status, age, hypertension, and body mass index, but not anthracycline chemotherapy. The total dose of anthracycline was independently associated with e’ septal and E/e’ septal: F(4.18) = 16.466 (p < 0.001; R² = 0.775) and F(3.16) = 7.271 (p = 0.004; R² = 0.627).
Conclusion. Left ventricular diastolic function worsens in women undergoing anthracycline-based chemotherapy for breast cancer (lower e’, e’/a’ lateral, and e’ septal, higher E/e’ septal ratio). However, anthracycline does not significantly affect LVEF and LV deformation indicators. E/e’ septalande’ septal are independently associated with the total dose of anthracycline.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics 2021. CA Cancer J Clin. 2021; 71(1): 7-33. doi: 10.3322/caac.21654

2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36): 2768-2801. doi: 10.1093/eurheartj/ehw211

3. Sinitsky MYu, Tsepokina AV, Khutornaya MV, Ponasenko AV, Sumin AN. Genetic basis of anthracyclines cardiotoxicity: Literature review. Acta biomedica scientifica. 2021; 6(4): 27-38. (In Russ.). doi: 10.29413/ABS.2021-6.4.3

4. Potter E, Marwick TH. Assessment of left ventricular function by echocardiography: the case for routinely adding global longitudinal strain to ejection fraction. JACC Cardiovasc Imaging. 2018; 11(2 Pt 1): 260-274. doi: 10.1016/j.jcmg.2017.11.017

5. de Souza TF, Silva TQ, Antunes-Correa L, Drobni ZD, Costa FO, Dertkigil SSJ, et al. Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy. Sci Rep. 2021; 11(1): 17132. doi: 10.1038/s41598-021-96630-y

6. Shah AM, Claggett B, Kitzman D, Biering-Sørensen T, Jensen JS, Cheng S, et al. Contemporary assessment of left ventricular diastolic function in older adults: The atherosclerosis risk in communities study. Circulation. 2017; 135(5): 426-439. doi: 10.1161/CIRCULATIONAHA.116.024825

7. Playford D, Strange G, Celermajer DS, Evans G, Scalia GM, Stewart S, et al. The NEDA investigators, diastolic dysfunction and mortality in 436 360 men and women: The National Echo Database Australia (NEDA). Eur Heart J Cardiovasc Imaging. 2021; 22(5): 505-515. doi: 10.1093/ehjci/jeaa253

8. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40(40): 3297-3317. doi: 10.1093/eurheartj/ehz641

9. Vasyuk YuA, Gendlin GE, Emelina EI, Shupenina EYu, Ballyuzek MF, Barinova IV, et al. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021; 26(9): 4703. (In Russ.). doi: 10.15829/1560-4071-2021-4703

10. Serrano JM, González I, Del Castillo S, Muñiz J, Morales LJ, Moreno F, et al. Diastolic dysfunction following anthracyclinebased chemotherapy in breast cancer patients: Incidence and predictors. Oncologist. 2015; 20(8): 864-872. doi: 10.1634/theoncologist.2014-0500

11. Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS One. 2017; 12(4): e0175544. doi: 10.1371/journal.pone.0175544

12. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020; 13(1 Pt 2): 198-210. doi: 10.1016/j.jcmg.2019.07.018

13. Barbosa MF, Fusco DR, Gaiolla RD, Werys K, Tanni SE, Fernandes RA, et al. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines. BMC Cardiovasc Disord. 2021; 21(1): 170. doi: 10.1186/s12872-021-01996-6

14. Mincu RI, Lampe LF, Mahabadi AA, Kimmig R, Rassaf T, Totzeck M. Left ventricular diastolic function following anthracycline-based chemotherapy in patients with breast cancer without previous cardiac disease: A meta-analysis. J Clin Med. 2021; 10(17): 3890. doi: 10.3390/jcm10173890

15. Pushkarev GS, Kuznetsov VA, Yaroslavskaya EI, Bessonov IS. Reliability and validity of Russian version of DS14 score for ischemic heart disease patients. Russian Journal of Cardiology. 2016; (6): 50-54. (In Russ.). doi: 10.15829/1560-4071-2016-6-50-54

16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 28(1): 1-39.e14. doi: 10.1016/j.echo.2014.10.003

17. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, ScherrerCrosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014; 15(10): 1063-1093. doi: 10.1093/ehjci/jeu192

18. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011; 130(3): 845-854. doi: 10.1007/s10549-011-1714-9

19. Dobson R, Ghosh AK, Ky B, Marwick T, Stout M, Harkness A, et al. British Society of Echocardiography; British Society of CardioOncology. British Society for Echocardiography and British CardioOncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Res Pract. 2021; 8(1): G1-G18. doi: 10.1530/ERP-21-0001

20. Yu AF, Ho AY, Braunstein LZ, Thor ME, Lee Chuy K, Eaton A, et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. J Am Soc Echocardiogr. 2019; 32(4): 521-528. doi: 10.1016/j.echo.2018.12.009

21. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31(2): 171-190. doi: 10.1016/j.annonc.2019.10.023

22. Sumin AN. Evaluating right ventricular function to reveal cancer therapy cardiotoxicity. Russian Open Medical Journal. 2021; 10(3): e0309. doi: 10.15275/rusomj.2021.0309

23. Sumin AN, Korok EV, Sergeeva TY. Impaired right ventricular filling in patients with a chronic coronary syndrome. Med Ultrason. 2021; 23(3): 311-318. doi: 10.11152/mu-2747

24. Yuzhalin AE. State-of-the-art technology for cardiovascular research. Complex Issues of Cardiovascular Diseases. 2021; 10(3): 103-108. doi: 10.17802/2306-1278-2021-10-3-103-108